Meihua International Medical Technologies Co., Ltd 6-K, filed Jan 3, 2025
Meihua International Medical Technologies Co., Ltd. (MHUAF)
About this 6-K
Meihua International Medical Technologies Co., Ltd filed this 6-K on January 3, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2025
Commission file number 001- 41291
Meihua International Medical Technologies Co., Ltd.
(Translation of registrant’s name into English)
88 Tongda Road, Touqiao Town
Guangling District, Yangzhou, 225000
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Effective December 26, 2024, Meihua International Medical Technologies Co., Ltd., a Cayman Islands company (the “Company”), entered into an amendment (the “Amendment”) to the securities purchase agreement, originally dated December 27, 2023 (the “SPA”), between the Company and Anson Investments Master Fund LP and Anson East Master Fund LP for the sale of up to $50.5 million in convertible notes and warrants. Under the Amendment, the parties agreed that there would only be the single $6,000,000 closing under the SPA, which occurred on January 2, 2024, and would be no additional closings under the SPA. A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
| Exhibit No. | Exhibit | |
| 10.1 | Amendment, dated December 26, 2024, between Meihua International Medical Technologies Co., Ltd. and the parties named therein. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Meihua International Medical Technologies Co., Ltd. | ||
| Dated: January 3, 2025 | By: | /s/ Xin Wang |
| Name: | Xin Wang | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
2
Exhibit 10.1
Amendment to the Securities Purchase Agreement
This agreement (the “Amendment”), effective December 26, 2024, hereby amends the securities purchase agreement, dated as of December 27, 2023 (the “Securities Purchase Agreement”), by and between Meihua International Medical Technologies Co., Ltd., a Cayman Islands exempted company (the “Company”), and each purchaser identified in the signature pages thereto (each a “Purchaser” and collectively the “Purchasers”). The Company and the Purchasers may be referred to herein as the “Parties.” Any terms not defined herein shall have the meaning set forth in the Securities Purchase Agreement.
WHEREAS, the Company originally entered into the Securities Purchase Agreement with the intent of selling the Purchasers up to $50.5 million in convertible notes, having closed on the initial sale of $6,000,000 in convertible notes (the “Issued Note”) on December 27, 2023; and
WHEREAS, as the Issued Note has since been paid in full and the Company, recognizing the deleterious effects on the Company’s stock price, does not wish to sell any further convertible notes to the Purchasers and the Purchasers do not wish to purchase any more convertible notes under the Securities Purchase Agreement; and
WHEREAS, recognizing the Issued Note is no longer outstanding and the Purchasers’ rights and protections in the Warrant are duly set forth in the Warrant itself, the Parties agree that certain restrictions from future offerings may be removed from the Securities Purchase Agreement.
NOW, THEREFORE, the Company and the Purchasers, for good and valuable consideration, agree to amend the Securities Purchase Agreement as follows:
1. Amendments. The Securities Purchase Agreement shall be amended and restated as follows:
Section 2.1(b) shall be removed in its entirety as follows:
“Section 2.1(b) [RESRVED].”
Section 2.1(c) shall be amended and restated as follows:
“Section 2.1(c) Maximum Subscription Amount. For the avoidance of doubt, it is the Parties’ intention that there will be a First Closing pursuant to which Purchaser’s Subscription Amount delivered by such Purchaser shall equal US$6,000,000. Thereafter, the Parties do not intend that there be any Additional Closing or Additional Closing Date.”
Section 4.12(h) shall be amended and restated as follows:
“Section 4.12(h) Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance. In addition, should the Company desire to pursue a Subsequent Financing in the future, and should Purchaser not accept the terms or otherwise choose not to participate in the Subsequent Financing, in no event will Purchaser take action to interfere with or otherwise restrict the Company’s ability to close on such Subsequent Financing.”
Section 4.13 shall be removed in its entirety as follows:
“Section 4.13 [RESERVED].”
2. This Amendment shall be read in conjunction with the Securities Purchase Agreement, with all sections of the Securities Purchase Agreement other than as set forth above to remain the same.
3. This Amendment does not constitute a waiver of, or a consent to, (i) any provision of the any of the Transaction documents not expressly referred to herein, or (ii) any present or future violation of, or defaults under, any provision of any of the Transaction Documents unless expressly referred to herein.
[Signature Page to Follow]
2
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered das of the day and year first written above.
| MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD. | |||
| By: | /s/ Xin Wang | ||
| Name: | Xin Wang | ||
| Title: | Chief Executive Officer | ||
| ANSON INVESTMENTS MASTER FUND LP | |||
| By: | /s/ Amin Nathoo | ||
| Name: | Amin Nathoo | ||
| Title: | Director of Anson Advisors Inc., co-investment advisor of Anson Investments Master Fund LP | ||
| ANSON EAST MASTER FUND LP | |||
| By: | /s/ Amin Nathoo | ||
| Name: | Amin Nathoo | ||
| Title: | Director of Anson Advisors Inc., co-investment advisor of Anson Investments Master Fund LP | ||
3